This article is a correction to:
Targeting HER3 to overcome EGFR TKI resistance in NSCLC
Qiuqiang Chen1*
Wenxue Ma- 1Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China
- 2Department of Medical Oncology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan, China
- 3Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, United States
A Corrigendum on
Targeting HER3 to overcome EGFR TKI resistance in NSCLC
By Chen Q, Jia G, Zhang X, and Ma W (2024) Front. Immunol. 14:1332057. doi: 10.3389/fimmu.2023.1332057
In the published article, there was an error in affiliation 1. Instead of “1”, it should be “3” only for the corresponding author Wenxue Ma. The correct affiliations of the authors are listed below.
Qiuqiang Chen1*, Gang Jia2, Xilin Zhang1, Wenxue Ma3*
1 Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China
2 Department of Medical Oncology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan, China
3 Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, United States
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR), tyrosine kinase inhibitors (TKIs), receptor tyrosine kinases (RTKs), resistance, human EGFR3 (HER3), antibody-drug conjugates (ADCs), Patritumab Deruxtecan (HER3-DXd)
Citation: Chen Q, Jia G, Zhang X and Ma W (2024) Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC. Front. Immunol. 15:1376045. doi: 10.3389/fimmu.2024.1376045
Received: 24 January 2024; Accepted: 25 January 2024;
Published: 31 January 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Chen, Jia, Zhang and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qiuqiang Chen, chenqiuq@hotmail.com; Wenxue Ma, wma@health.ucsd.edu